On July 21, 2026 AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, reported that updated clinical results from the Phase 1b TheraPb trial (NCT05720130) evaluating 212Pb-ADVC001 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) have been accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, held October 23–27, 2026, in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will include updated results from the dose-escalation portion of the TheraPb study. The data represents the first long-term follow-up of a targeted alpha therapy study employing a novel design escalating both administered activities and dose schedules, supporting the recommended Phase 2 dose and regimen. The presentation builds on previously reported encouraging Phase 1b data and supports the continued clinical development of 212Pb-ADVC001, currently enrolling Phase 2 evaluating a novel dosing regimen of intensified induction and adaptive dosing strategies.
ESMO 2026 Presentation Details
Title: Updated Results from the TheraPb Trial Defining the Recommended Phase 2 Dose (RP2D) of 212Pb-ADVC001 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presentation Number: 2253P
Presentation Type: Poster Presentation
Location: Madrid, Spain
Date/Time: 23 October 2026 / 3:15 – 4:00 PM CET
(Press release, Advancell, JUL 21, 2026, View Source [SID1234669350])